UK-based Verona Pharma has scored a key win in a phase 3 trial of its chronic obstructive pulmonary disease (COPD) drug ensifentrine, setting up regulatory filings in the first half of next year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback